Summary

  • With longer term follow-up at 46.9 months, median PFS was significantly longer for A-containing arms vs O-Clb (NR vs 27.8 months) which was consistent across high-risk and other genetic subgroups1,2 
  • At 48 months, estimated PFS rates were in favor of A-O over A (87% vs 78%)1,2
  • ORR was significantly higher in A-containing arms vs O-Clb1,2
  • OS rates were high in the A-O vs O-Clb arms with fewer deaths occurred in patients who received A-O. However, statistical significance was not reached with any arm1,2
  • Incidences of cardiovascular events (atrial fibrillation & hypertension) and rates of treatment discontinuations were low with A-containing arms which is consistent with the interim findings1,2
  • Despite the higher CR rate, grade ≥3 infections occurred at a higher incidence with A-O compared with A alone (24% vs 16%)1,2

Abbreviations

A = acalabrutinib

;

Clb = chlorambucil

;

CR = complete response

;

NR = not reached

;

O = obinutuzumab

;

ORR = overall response rate

;

OS = overall survival 

;

PFS = progression-free survival

;

vs = versus

References

1. Sharman J, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus obinutuzumab with chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up [oral presentation]. Presented at: American Society of Clinical Oncology (ASCO) Virtual Annual Meeting; June 4-8, 2021. Chicago, IL. Abs 7509.
2. Sharman JP, Egyed M, Jurczak W et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-nave chronic lymphocytic leukemia (ELEVATE TN): a randomized, controlled phase 3 trial [article and supplementary appendix]. Lancet. 2020;395:1278-91.

Document ID: 780f9b60-d375-4516-97d6-9ba58f025de4
Last updated: 17-April-2023

Disclaimers

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

©2023 AstraZeneca. All rights reserved.